This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineSGN-CEACAM5C
an investigational topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
SGNCEA5C-001: Advanced solid tumors
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources
Detailed information about SGN-CEACAM5C clinical trials
Related Links